Atara Biotherapeutics, Inc. (ATRA) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is neutral — 3 Buy, 7 Hold, 3 Sell.
The consensus price target is $15.50 (low: $6.00, high: $25.00), representing an upside of 195.8% from the current price $5.24.
Analysts estimate Earnings Per Share (EPS) of $-7.33 and revenue of $0.12B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-11.41 vs est $-7.33 (missed -55.6%). 2025: actual $2.61 vs est $2.87 (missed -9%). Analyst accuracy: 77%.
ATRA Stock — 12-Month Price Forecast
$15.50
▲ +195.80% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Atara Biotherapeutics, Inc., the average price target is $15.50, with a high forecast of $25.00, and a low forecast of $6.00.
The average price target represents a +195.80% change from the last price of $5.24.
Highest Price Target
$25.00
Average Price Target
$15.50
Lowest Price Target
$6.00
ATRA Analyst Ratings
Hold
Based on 13 analysts giving stock ratings to Atara Biotherapeutics, Inc. in the past 3 months
EPS Estimates — ATRA
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$11.41
vs Est –$7.33
▼ 35.7% off
2025
Actual $2.61
vs Est $2.87
▼ 9.8% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — ATRA
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.129B
vs Est $0.117B
▲ 9.5% off
2025
Actual $0.121B
vs Est $0.122B
▼ 0.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
